VivoSeq
Other

Caffeine

0

Pipeline Programs↗

10

Active Trials↗

6

Companies Involved↗

Caffeine is an early-stage landscape with 0 programs across 6 companies. The most active players are Astellas, Boehringer Ingelheim, Pfizer.

Intelligence

Pipeline Metrics

Competitive Density

27/100

Pipeline Velocity

27/100

Mech. Concentration

N/A

Completion Rate

90/100

Attrition Rate

4/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

Astellas logo

Astellas

0 programs

PreclinicalBoehringer Ingelheim logo

Boehringer Ingelheim

0 programs

PreclinicalPfizer logo

Pfizer

0 programs

PreclinicalP

Prana Biotechnology Limited

0 programs

PreclinicalK

Kaken Pharmaceutical

0 programs

PreclinicalT

Tobira Therapeutics, Inc.

0 programs

Preclinical

Pipeline

Programs by Phase

No pipeline programs currently tracked for this disease.

Analysis

Trial Status

49

clinical trials

Completed28 · 57%
Unknown status8 · 16%
Not yet recruiting4 · 8%
Recruiting3 · 6%
Active, not recruiting2 · 4%
Enrolling by invitation1 · 2%
Other3 · 6%

Clinical Trials

Trial Activity

49 trials

Effect of Caffeine on Cold-stimulated Brown Adipose Tissue Activity
Recruiting·UUniversity Hospital, Basel, Switzerland·N/A·NCT06978777·12 enrolled
Effects of Caffeine on Reinforcement Learning in Healthy Adults Using PET/MRI
Recruiting·—·Phase 4·NCT06763172·12 enrolled
Dose Optimization of Caffeine for HIE
Recruiting·UUniversity of North Carolina, Chapel Hill·Phase 1·NCT06448780·16 enrolled
Caffeine Use in the Management of Preterm Infants
Active, not recruiting·UUniversity of California, Irvine·Phase 2·NCT06327152·80 enrolled
Effects of Caffeine Ingestion on Morning Cognitive and 4-km Time Trial Performance in Males
Active, not recruiting·LLiverpool John Moores University·Phase 1/2·NCT07469852·15 enrolled
Improving Preterm Kidney Outcomes With Caffeine
Not yet recruiting·UUniversity of Wisconsin, Madison·Phase 2·NCT07262060·102 enrolled
Caffeine for Infants Born at 28 to 34 Weeks Receiving Respiratory Support
Not yet recruiting·QQueen's University·Phase 2·NCT07456670·62 enrolled
Caffeine Strategies and Fat Oxidation
Not yet recruiting·UUniversidad Rey Juan Carlos·N/A·NCT07402902·10 enrolled
Caffeine Optimization for Oxygen Saturation Index in ELBW Infants
Not yet recruiting·UUniversity of Rochester·Phase 2·NCT07216365·40 enrolled
Effects of Caffeine Ingestion on Morning Cognitive and Muscle Repeated Sprint Performance in Males
Enrolling by invitation·LLiverpool John Moores University·Phase 1·NCT07466732·15 enrolled
Caffeine and Cerebrovascular Reactivity
Completed·UUniversity of Oklahoma·Phase 1·NCT04730193·10 enrolled
Study to Evaluate the Effect of Multiple Doses of BIRT 2584 XX Tablets on the Pharmacokinetic Parameters of Warfarin, Omeprazole, Caffeine, and Dextromethorphan in Healthy Male Volunteers
Completed·Boehringer Ingelheim logoBoehringer Ingelheim·Phase 1·NCT02256813·20 enrolled
A Study to Estimate the Effect of Multiple Dose Abrocitinib on Caffeine, Efavirenz, and Omeprazole in Healthy Participants
Completed·Pfizer logoPfizer·Phase 1·NCT05067439·26 enrolled
Caffeine's Effect on Regadenoson Administration With Single Photon Emission Computed Tomography (SPECT) Myocardial Perfusion Imaging (MPI)
Completed·Astellas logoAstellas·Phase 3·NCT00826280·347 enrolled
The Pharmacodynamics of Cannabinoid-Caffeine Combinations
Completed·JJohns Hopkins University·Phase 1·NCT05478863·20 enrolled
Page 1 of 4

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)